Study of oral cholesterol-lowering pill in children with HeFH
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests an experimental daily pill (enlicitide decanoate) that lowers LDL ('bad') cholesterol in children and teens with a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It aims to see if this medicine can safely help reduce their high cholesterol levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have a confirmed diagnosis of heterozygous familial hypercholesterolemia (HeFH), either by a doctor's evaluation or a genetic test.
- Your child's 'bad' cholesterol (LDL-C) level must be 130 mg/dL or higher on a fasting blood test.
- Your child must be on a stable dose of cholesterol-lowering medication(s) for at least 30 days before the trial starts, with no planned changes during the study.
- Your child must be taking an optimized daily dose of statin (maybe with other meds), or if statins are not possible, must have documented intolerance to at least two different statins (or one statin plus a refusal to take statins) and be on other cholesterol-lowering medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental medication called QLC7401 for people with a genetic condition that causes very high cholesterol. It aims to lower cholesterol levels safely and may be an option for those who need better control.
This study is a long-term follow-up for children and teens with familial hypercholesterolemia (a genetic condition causing very high cholesterol) who have already completed a previous study. It tests the safety and effectiveness of an investigational drug called lerodalcibep over a longer period.
This study tests a new injection called SYH2053 for people with HeFH, a genetic condition that causes very high cholesterol. It looks at whether the injection can safely lower LDL cholesterol when added to standard statin therapy.
This study looks at how familial hypercholesterolemia (a genetic condition that causes high cholesterol) affects mothers and their newborns. It aims to learn more about cholesterol levels during pregnancy and the baby's first week of life.
This trial tests if a new medicine, lerodalcibep, can safely lower cholesterol in children ages 6 to 17 who have a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It aims to help children whose cholesterol stays high despite taking standard cholesterol-lowering drugs.
This trial tests a new medicine called inclisiran to lower very high cholesterol in children aged 2 to 12 who have a specific genetic condition (homozygous familial hypercholesterolemia, or HoFH). You may not need to change your current cholesterol treatments, and the study will check if inclisiran can help reduce your LDL cholesterol further.
Hear when a new Heterozygous Familial Hypercholesterolemia (HeFH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.